317 related articles for article (PubMed ID: 7625729)
21. Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives.
Schoonen WG; Deckers GH; de Gooijer ME; de Ries R; Kloosterboer HJ
J Steroid Biochem Mol Biol; 2000 Nov; 74(4):213-22. PubMed ID: 11162927
[TBL] [Abstract][Full Text] [Related]
22. Dihydrospirorenone (ZK30595): a novel synthetic progestagen--characterization of binding to different receptor proteins.
Pollow K; Juchem M; Elger W; Jacobi N; Hoffmann G; Möbus V
Contraception; 1992 Dec; 46(6):561-74. PubMed ID: 1493716
[TBL] [Abstract][Full Text] [Related]
23. Experimental studies on the endocrine side effects of new aldosterone antagonists.
Nishino Y; Schröder H; el Etreby MF
Arzneimittelforschung; 1988 Dec; 38(12):1800-5. PubMed ID: 3245852
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol.
Rosenbaum P; Schmidt W; Helmerhorst FM; Wuttke W; Rossmanith W; Freundl F; Thomas K; Grillo M; Wolf A; Heithecker R
Eur J Contracept Reprod Health Care; 2000 Mar; 5(1):16-24. PubMed ID: 10836659
[TBL] [Abstract][Full Text] [Related]
25. Medroxyprogesterone acetate but not drospirenone ablates the protective function of 17 beta-estradiol in aldosterone salt-treated rats.
Arias-Loza PA; Hu K; Schäfer A; Bauersachs J; Quaschning T; Galle J; Jazbutyte V; Neyses L; Ertl G; Fritzemeier KH; Hegele-Hartung C; Pelzer T
Hypertension; 2006 Nov; 48(5):994-1001. PubMed ID: 17000933
[TBL] [Abstract][Full Text] [Related]
26. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
27. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure.
Oelkers WK
Steroids; 1996 Apr; 61(4):166-71. PubMed ID: 8732994
[TBL] [Abstract][Full Text] [Related]
28. The pharmacology of nomegestrol acetate.
Ruan X; Seeger H; Mueck AO
Maturitas; 2012 Apr; 71(4):345-53. PubMed ID: 22364709
[TBL] [Abstract][Full Text] [Related]
29. Effects of antiandrogenic progestins, chlormadinone and cyproterone acetate, and the estrogen 17α-ethinylestradiol (EE2), and their mixtures: Transactivation with human and rainbowfish hormone receptors and transcriptional effects in zebrafish (Danio rerio) eleuthero-embryos.
Siegenthaler PF; Bain P; Riva F; Fent K
Aquat Toxicol; 2017 Jan; 182():142-162. PubMed ID: 27907851
[TBL] [Abstract][Full Text] [Related]
30. Multiple actions of synthetic 'progestins' on the growth of ZR-75-1 human breast cancer cells: an in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids.
Poulin R; Baker D; Poirier D; Labrie F
Breast Cancer Res Treat; 1991; 17(3):197-210. PubMed ID: 1645605
[TBL] [Abstract][Full Text] [Related]
31. Effects of drospirenone on cardiovascular markers in human aortic endothelial cells.
Seeger H; Wallwiener D; Mueck AO
Climacteric; 2009 Feb; 12(1):80-7. PubMed ID: 18979300
[TBL] [Abstract][Full Text] [Related]
32. Drospirenone: a novel progestogen used as an oral contraceptive without an estrogen component.
Paton DM
Drugs Today (Barc); 2020 May; 56(5):321-328. PubMed ID: 32406879
[TBL] [Abstract][Full Text] [Related]
33. Nomegestrol acetate, a novel progestogen for oral contraception.
Mueck AO; Sitruk-Ware R
Steroids; 2011 May; 76(6):531-9. PubMed ID: 21335021
[TBL] [Abstract][Full Text] [Related]
34. Nortestosterone-derived synthetic progestogens do not activate the progestogen receptor of Murray-Darling rainbowfish (Melanotaenia fluviatilis) but are potent agonists of androgen receptors alpha and beta.
Bain PA; Kumar A; Ogino Y; Iguchi T
Aquat Toxicol; 2015 Jun; 163():97-101. PubMed ID: 25863598
[TBL] [Abstract][Full Text] [Related]
35. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome.
Caprio M; Antelmi A; Chetrite G; Muscat A; Mammi C; Marzolla V; Fabbri A; Zennaro MC; Fève B
Endocrinology; 2011 Jan; 152(1):113-25. PubMed ID: 21084448
[TBL] [Abstract][Full Text] [Related]
36. The role of antiandrogens in hormone replacement therapy.
Schneider HP
Climacteric; 2000 Dec; 3 Suppl 2():21-7. PubMed ID: 11379383
[TBL] [Abstract][Full Text] [Related]
37. Comparative effects of chlormadinone acetate and its 3alpha- and 3beta-hydroxy metabolites on progesterone, androgen and glucocorticoid receptors.
Schneider J; Kneip C; Jahnel U
Pharmacology; 2009; 84(2):74-81. PubMed ID: 19590256
[TBL] [Abstract][Full Text] [Related]
38. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy.
DeManno D; Elger W; Garg R; Lee R; Schneider B; Hess-Stumpp H; Schubert G; Chwalisz K
Steroids; 2003 Nov; 68(10-13):1019-32. PubMed ID: 14667995
[TBL] [Abstract][Full Text] [Related]
39. Added benefits of drospirenone for compliance.
Foidart JM
Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
[TBL] [Abstract][Full Text] [Related]
40. Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy.
Lello S
Drugs; 2010 Mar; 70(5):541-59. PubMed ID: 20329803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
